Bimzelx

RSS

bimekizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Bimzelx is a medicine used to treat plaque psoriasis, a disease that causes red, scaly patches on the skin. It is used in adults with moderate to severe disease who need systemic treatment (treatment with medicines affecting the whole body).

Bimzelx contains the active substance bimekizumab.

This EPAR was last updated on 17/05/2022

Authorisation details

Product details
Name
Bimzelx
Agency product number
EMEA/H/C/005316
Active substance
Bimekizumab
International non-proprietary name (INN) or common name
bimekizumab
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AC
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
UCB Pharma S.A.  
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
20/08/2021
Contact address

UCB Pharma S.A.
Allee de la Recherche 60
B-1070 Bruxelles
Belgium

Product information

24/03/2022 Bimzelx - EMEA/H/C/005316 - II/0002

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating
1 rating